In a very unusual move, the tax inversion giant, Mylan, announced it’d launch a generic version of the Epipen, to cannibalize its own branded drug, at the reduced cost of $300. Compared to the branded price tag of $608, $300 seems like a bargain. However, bear in mind, when Mylan acquired this drug in 2007, the price tag was $100.
Our decision to launch a generic alternative to EpiPen is an extraordinary commercial response,” Bresch said on Monday. “We determined that bypassing the brand system in this case and offering an additional alternative was the best option.”
This is a very greedy move by Bresch. By refusing to cut the price of the branded version, she ensures that a certain percentage of people will continue to buy it at the elevated price. If you needed the Epipen for your daughter or son, would you take the chance with an unknown generic version, which is often synonymous with low quality, or pay up for the life saving branded version?
Exactly.
Shares of MYL are higher by 2% this morning.
If you enjoy the content at iBankCoin, please follow us on Twitter
You are 100% safe buying the generic version. It’s going to be made by Mylan. Even if it wasn’t Mylan, the difference would be in the packaging or the pen itself. The raw drug all comes from the same place.
I know that, but does Jane Smith from Ohio know that?
Fair enough.
In some cases it’s not the same and I have friends that generic did not work the same as blood pressure brand name. I’m with Fly and if I have the money I go with Brand name when it come to family health!
This is why she chose to do this. It’s not like this is anti biotics. This is time sensitive, life saving, medicine. By doing this, instead of reducing the cost of Epipen, she ensures a higher unit price.
Free market, bitches.